KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo

KOBAYASHI PHARMACEUTICAL CO.,LTD.

Manufactures OTC pharma, personal care, and household goods for niche consumer markets.

4967 | T

Overview

Corporate Details

ISIN(s):
JP3301100008
LEI:
Country:
Japan
Address:
大阪市中央区道修町4丁目4番10号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kobayashi Pharmaceutical Co., Ltd. is a manufacturer and distributor of consumer products specializing in niche markets. The company's portfolio includes over-the-counter (OTC) pharmaceuticals, health and personal care items, and household goods. It is recognized for developing and marketing innovative products that address specific consumer needs and lifestyles, such as disposable body warmers, deodorizing air fresheners, and other personal wellness solutions. The company operates through various segments, including the manufacturing and sales of domestic household products.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 08:30
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-08-08 08:30
Interim Report
半期報告書-第108期(2025/01/01-2025/12/31)
Japanese 226.4 KB
2025-03-31 08:27
Post-Annual General Meeting Information
臨時報告書
Japanese 25.4 KB
2025-03-28 07:33
Registration Form
確認書
Japanese 8.2 KB
2025-03-28 07:32
Governance Information
内部統制報告書-第107期(2024/01/01-2024/12/31)
Japanese 22.2 KB
2025-03-28 07:32
Annual Report
有価証券報告書-第107期(2024/01/01-2024/12/31)
Japanese 2.1 MB
2025-02-20 08:51
Post-Annual General Meeting Information
臨時報告書
Japanese 25.1 KB
2025-02-10 07:32
Legal Proceedings Report
訂正臨時報告書
Japanese 24.5 KB
2025-01-21 09:01
Board/Management Information
臨時報告書
Japanese 20.7 KB
2024-12-26 05:03
Major Shareholding Notification
臨時報告書
Japanese 20.5 KB
2024-11-08 07:41
Legal Proceedings Report
訂正臨時報告書
Japanese 24.1 KB
2024-08-09 08:00
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-08-09 08:00
Interim Report
半期報告書-第107期(2024/01/01-2024/12/31)
Japanese 240.4 KB
2024-08-08 08:30
Legal Proceedings Report
訂正臨時報告書
Japanese 24.0 KB
2024-07-23 08:29
Board/Management Information
臨時報告書
Japanese 20.9 KB

Automate Your Workflow. Get a real-time feed of all KOBAYASHI PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOBAYASHI PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOBAYASHI PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Genmab Logo
Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.
Denmark
GMAB
GENOLUTION INC. Logo
Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.
South Korea
225220
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea
314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea
228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland
GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea
066830
Genprex, Inc. Logo
A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.
United States of America
GNPX
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway
GENT
GERON CORP Logo
Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.
United States of America
GERN
GH Research PLC Logo
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
United States of America
GHRS

Talk to a Data Expert

Have a question? We'll get back to you promptly.